ArticleAmerican journal of translational research2025
Predictive value of modified early warning score and risk stratification for adverse cardiovascular events in acute chest pain patients.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Predictive Value of Combined MEWS and NIPDS Scores for 24-Hour Clinical Deterioration in Emergency Observation Patients: A Prospective Cohort Study.Journal of multidisciplinary healthcare · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo assess the prognostic value of the modified early warning score (MEWS) in predicting major adverse cardiovascular events (MACE) within one month of admission, compared to established cardiac risk scores.
methodsThis retrospective study included 565 adults with acute chest pain who visited the Emergency Department between January 2023 and January 2024. Baseline demographics, medical history, vital signs, and clinical scores were collected. Patients were classified based on the occurrence of MACE - defined as cardiac death, ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), or coronary revascularization - within one month.
resultsOf the 565 patients, 112 (19.8%) experienced MACE. Patients in the MACE group had significantly higher clinical scores (all P<0.05). The MEWS score exhibited the strongest association with MACE (rho = 0.451, P<0.001) and remained a significant predictor in multivariate logistic regression (odds ratio = 4.416; 95% CI, 3.006-6.488; P<0.001). MEWS demonstrated the highest discriminative ability (area under the curve [AUC] = 0.826) compared to other scores tested. Random forest analysis confirmed MEWS as the most important predictor of MACE.
conclusionThe MEWS score outperforms traditional cardiac risk assessment tools in early prediction of major adverse cardiovascular events in acute chest pain patients. Its use could enhance risk stratification and inform clinical decision-making in emergency settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.